| ￥3500 | |
| Z04898-100 | |
|
|
|
|
|
|
|
|
|
| Species | Cynomolgus | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. Measured by its ability to cleave a peptide substrate,NcarbobenzyloxyGlyGlyArg7amido4methylcoumarin (ZGGRAMC). Test result meets the standard. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 47.23 kDa | ||||
| Apparent Molecular Weight | Due to protein lysis and glycosylation, the protein migrates to 23-25 kDa (long chain A), 35-40 kDa (chain B) and 50-60 kDa (long chain A&chain B) based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized PLAU/uPA (active form), His, Cynomolgus, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for Human uPAR, hFc Tag with the EC50 of 21.4ng/ml determined by ELISA. »
The purity of PLAU/uPA (active form), His, Cynomolgus is greater than 95% as determined by SEC-HPLC. »
PLAU/uPA (active form), His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
Cynomolgus uPAR, His Tag immobilized on CM5 Chip can bind PLAU/uPA (active form), His, Cynomolgus, His Tag with an affinity constant of 0.033 nM as determined in SPR assay (Biacore T200). »
| Target Background | Plasminogen activator, urokinase (uPA) is a secreted serine protease whose Dysregulation is often accompanied by various cancers. PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC. |
| Synonyms | PLAU; Urokinase; ATF; UPA; URK; u-PA; BDPLT5; QPD |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
